NEW YORK, July 24 (Praxis Press) Previous reports have documented that sodium cromoglicate has antisickling activity in vitro. Toppet and colleagues studied this antisickling activity in sickle-cell patients given sodium cromoglicate by inhalation or nasal route. Both treatments significantly decreased the percentage of sickle cells in venous blood; this effect was largely retained when the blood was deoxygenated. Sodium cromoglicate may be a clinically useful antisickling drug that has the added benefits of low toxicity and low cost.

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?